close Icon


Despite progress in preventing and treating malaria, over 600,000 people die each year from the disease, mostly young children. Every 75 seconds, a child under 5 loses their life to this preventable and curable disease. Malaria is a mosquito-borne disease impacting more than 80 countries, many in our region. Burnet is committed to helping achieve global malaria elimination targets.

Our main objectives are to:

  • achieve major new advances to strengthen diagnosis, treatment and prevention of malaria through innovative research
  • contribute to the World Health Organization's (WHO’s) global elimination targets of a 90 per cent reduction in malaria incidence and mortality. This will be achieved through discovery-based laboratory and translation research, and in-field education, prevention and treatment public health programs
  • support national malaria control programs in our region in reaching the WHO elimination targets.

To achieve our goals, we work with partners in Australia and internationally, especially in malaria-endemic regions in the Pacific, Southeast Asia and East Africa. We also collaborate with industry partners to develop vaccines, diagnostics and therapeutics. Burnet’s Malaria Program focuses on five main areas:

  1. Diagnostics:
    • Creating new malaria diagnostics and tools and strategies for improved malaria treatment and enhanced surveillance. 

  2. Vaccines:
    • Understanding immunity to malaria to develop effective vaccines against the two major causes of human malaria, Plasmodium falciparum and Plasmodium vivax.
    • Advancing the development and evaluation of leading malaria vaccine candidates.

  3. Drugs and Drug Resistance
    • Developing new antimalarial drugs and tracking and preventing the spread of drug resistance, especially in the Asia-Pacific region.

  4. Prevention and Surveillance 
    • Establishing surveillance and response systems to improve malaria control efficiency and fast-track the pathways to elimination.
    • Developing and evaluating improved malaria prevention strategies. 

  5. Community Empowerment
    • Operational and implementation research to increase access to quality health care services and malaria prevention.
    • Supporting improved health behaviours, strengthening health systems and delivery of health care, and supporting communities in malaria elimination activities.

Together, here are some of the ways we’ve made a positive contribution towards reaching the global malaria elimination targets

  • discovered new insights into how drug resistance may emerge in populations and how to better quantify and monitor its spread
  • identified new antimalarial compounds with the potential for development into drugs, such as malaria tablets
  • identified immune responses that protect against malaria and new approaches for vaccine development
  • developed new low-cost diagnostic tests to guide the treatment of malaria
  • developed novel tools to enhance surveillance and tracking of malaria in populations
  • created strategies in affected communities to address gaps in health services and coverage to improve diagnosis, treatment, and prevention.

participants recruited so far in a cross-sectional survey of pregnant women in Papua New Guinea to evaluate a Highly Sensitive Rapid Diagnostic Test for malaria.


malaria projects supported by Burnet with a focus on creating the greatest impact on the health of resource-poor communities like Papua New Guinea.


antigen combinations examined by Burnet researchers to identify those most promising for malaria vaccine development.


is the number of core proteins in PTEX, a parasite gateway discovered by Burnet researchers. PTEX serves as an entry point for the malaria parasite into red blood cells.

Working Groups

Burnet is an Australian-based medical research and public health institute and international non-government organisation that is working towards a more equitable world through better health.

510X288 PAVE Left Corner Element Circle Name 2 (1)
PAVE PNG - Partnership for Vivax Elimination
PROJECT Arrow Icon
NATNAT: Newly Adapted Tools and Network Against Mosquito Borne Disease Transmission
PROJECT Arrow Icon
Malaria In Png Cpop 2 (1)
Discovering the mechanisms and targets of immunity against malaria
PROJECT Arrow Icon
Project Image Option 1 Vaccines Against Malaria Caused By Plasmodium Falciparum And P.Vivix
Vaccines against malaria caused by Plasmodium falciparum and P. vivax
PROJECT Arrow Icon
Project Image Understanding Malaria Transmission And Immunity To Inform Malaria Elimination
Understanding malaria transmission and immunity to inform malaria elimination
PROJECT Arrow Icon
Holding Image
Developing a novel assessment tool to evaluate health system’s readiness of the countries in Greater Mekong Subregion to enter malaria elimination phase
PROJECT Arrow Icon
Holding Image
Immunity to malaria and infectious diseases during pregnancy
PROJECT Arrow Icon
Holding Image
Immunity, drug efficacy and spread of antimalarial drug resistance
PROJECT Arrow Icon
Rebound 510X288
Impact of declining transmission on immunity and risk of malaria rebound
PROJECT Arrow Icon
Holding Image
Integrating molecular and serological detection of malaria into national surveillance systems
PROJECT Arrow Icon
Holding Image
Optimising malaria surveillance and response strategies to achieve elimination
PROJECT Arrow Icon
Holding Image
Preventing malaria transmission in high-risk populations
PROJECT Arrow Icon
Serosurveillance 510X288
Serological surveillance to identify mosquito exposure and malaria transmission
PROJECT Arrow Icon